According to the latest report by IMARC Group, titled "Acne Vulgaris Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2033," the global acne vulgaris market size is witnessing steady growth. Acne vulgaris is an inflammatory skin disorder and primarily triggered by Cutibacterium acnes. It comprises the formation of comedones, papules, pustules, and frequent cysts as a result of the obstruction and inflammation caused in the pilosebaceous units. It occurs through excess sebum production, follicular plugging with sebum and keratinocytes, colonization of follicles with acne-causing bacteria, and release of numerous inflammatory mediators. It is initiated when the bacterium breaks down sebum into free fatty acids that irritate the follicular epithelium and elicit an inflammatory response by neutrophils and then lymphocytes, which further disrupts the epithelium. It is primarily triggered during the onset of puberty when numerous hormonal changes take place in the body and due to excessive sweating in humid conditions. It is often treated with various topical agents, such as benzoyl peroxide, antibiotics, retinoids, and salicylic acid. It can also be cured with system therapy, such as oral antibiotics, hormonal therapy, and isotretinoin, depending on the requirements of the patients.
Global Acne Vulgaris Market Trends:
At present, the increasing occurrence of acne vulgaris in individuals due to the consumption of unhealthy diets and the adoption of sedentary lifestyle habits represents one of the primary factors strengthening the growth of the market. Besides this, the rising concern about the physical appearances of individuals around the world is propelling the growth of the market. In addition, the growing awareness about the symptoms and treatment of acne vulgaris among the masses is offering a favorable market outlook. Apart from this, the wide availability of various anti-acne skin care products, such as facewash, serums, ointments, creams, and lotions, is contributing to the growth of the market. Additionally, the increasing production of acne treatment products consisting of various active ingredients, such as benzoyl peroxide, retinoid, glycolic acid, and lactic acid, along with witch hazel, to reduce inflammation, is supporting the growth of the market. Moreover, the rising popularity of various skin therapies to treat severe acne, such as light amplification by stimulated emission of radiation (LASER) therapy, steroid injections, and chemical peel treatments, is bolstering the growth of the market.
Market Summary:
- Region-wise, the market has been classified into the United States, EU5 (Germany, France, the United Kingdom, Italy, and Spain), and Japan. The United States has the largest patient population for acne vulgaris and also represents the largest market for its treatment among the seven major markets.
- This research study also offers a thorough overview of late-stage pipeline candidates and currently marketed medications for acne vulgaris.
- The study also offers a thorough overview of the treatment practices for acne vulgaris, the share of specific therapies, and the performance of key market players.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800